Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

Farmer, Hannah, McCabe, Nuala, Lord, Christopher J., Tutt, Andrew N. J., Johnson, Damian A., Richardson, Tobias B., Santarosa, Manuela, Dillon, Krystyna J. +6 more·2005·Nature

DOI 10.1038/nature03445

Cited by (1,041)

Items 301–400 of 1,041

Hypoxia-Induced Down-regulation of BRCA1 Expression by E2Fs
Ranjit S. Bindra, Shannon L. Gibson, Alice X. Meng, Ulrica Westermark, Maria Jasin, Andrew J. Pierce, Robert Glen Bristow, Marie K. Classon, Peter M. Glazer · 2005 · Cancer Research
EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation
Beatrice Rondinelli, Ewa Gogola, Hatice Yücel, Alexandra A. Duarte, Marieke van de Ven, Roxanne van der Sluijs, Panagiotis A. Konstantinopoulos, Jos Jonkers, Raphaël Ceccaldi, Sven Rottenberg et al. · 2017 · Nature Cell Biology
Predictive biomarkers: a paradigm shift towards personalized cancer medicine
Nicholas Barrie La Thangue, David James Kerr · 2011 · Nature Reviews Clinical Oncology
EWS–FLI1 increases transcription to cause R-loops and block BRCA1 repair in Ewing sarcoma
Aparna Gorthi, July Carolina Romero, Eva Loranc, Lin Cao, Liesl A. Lawrence, Elicia Goodale, Amanda Balboni Iniguez, Xavier Bernard, V. Pragathi Masamsetti, Sydney R. Roston et al. · 2018 · Nature
PARP Inhibitors: Extending Benefit Beyond BRCA -Mutant Cancers
Patrick Glen Pilie, Carl Michael Gay, Lauren A. Byers, Mark J. O’Connor, Timothy Anthony Yap · 2019 · Clinical Cancer Research
The plasticity of DNA replication forks in response to clinically relevant genotoxic stress
Matteo Berti, David Cortez, Massimo Lopes · 2020 · Nature Reviews Molecular Cell Biology
PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer
Chabanon, Roman M., Muirhead, Gareth, Krastev, Dragomir B., Adam, Julien, Morel, Daphné, Garrido, Marlène, Lamb, Andrew, Hénon, Clémence, Dorvault, Nicolas, Rouanne, Mathieu et al. · 2019 · Journal of Clinical Investigation
Advances in the Systemic Treatment of Triple-Negative Breast Cancer
J.M. Lebert, Renee Elizabeth Lester, Erin Diana Powell, Melanie Seal, Joy S. McCarthy · 2018 · Current Oncology
Genomic Scars as Biomarkers of Homologous Recombination Deficiency and Drug Response in Breast and Ovarian Cancers
Watkins, Johnathan A, Irshad, Sheeba, Grigoriadis, Anita, Tutt, Andrew NJ · 2014 · Breast Cancer Research
A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer
Monika Graeser, Afshan McCarthy, Christopher J. Lord, Kay Savage, Margaret Hills, Janine Salter, Nick Orr, Marina Parton, Ian E. Smith, Jorge Sergio Reis-Filho et al. · 2010 · Clinical Cancer Research
PARP-3 and APLF Function Together to Accelerate Nonhomologous End-Joining
Stuart L. Rulten, Anna E.O. Fisher, Isabelle Robert, Maria C. Zuma, Michèle Rouleau, Limei Ju, Guy G. Poirier, Bernardo Reina‐San‐Martin, Keith W. Caldecott · 2011 · Molecular Cell
Cell death pathways: intricate connections and disease implications
Matthias Kist, Domagoj Vucic · 2021 · The EMBO Journal
The role of PARP in DNA repair and its therapeutic exploitation
Milind M. Javle, Nicola J. Curtin · 2011 · British Journal of Cancer
Effect of BRCA1/2 Mutations on Long-Term Survival of Patients With Invasive Ovarian Cancer: The National Israeli Study of Ovarian Cancer
Angela Chetrit, Galit Hirsh‐Yechezkel, Yehuda Ben‐David, Flora Lubin, Eitan Friedman, Siegal Sadetzki · 2007 · Journal of Clinical Oncology
A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor
Nicholas C. Turner, Christopher J. Lord, Elizabeth J. Iorns, Rachel Brough, Sally Swift, Richard J. R. Elliott, Sydonia Rayter, Andrew N.J. Tutt, Alan Ashworth · 2008 · The EMBO Journal
Function of BRCA1 in the DNA Damage Response Is Mediated by ADP-Ribosylation
Mo Li, Xiaochun Yu · 2013 · Cancer Cell
Discovery of 2-{4-[(3S)-Piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): A Novel Oral Poly(ADP-ribose)polymerase (PARP) Inhibitor Efficacious in BRCA-1 and -2 Mutant Tumors
PHILIP G. JONES, Sergio Altamura, Julia K. Boueres, Federica Ferrigno, Massimiliano Fonsi, Claudia Giomini, Stefania Lamartina, Edith S. Monteagudo, Jesus M. Ontoria, Maria Vittoria Orsale et al. · 2009 · Journal of Medicinal Chemistry
Hereditary breast cancer: new genetic developments, new therapeutic avenues
Philippe M. Campeau, William D. Foulkes, Marc D. Tischkowitz · 2008 · Human Genetics
New Strategies for Triple-Negative Breast Cancer—Deciphering the Heterogeneity
Ingrid A. Mayer, Vandana Gupta Abramson, Brian David Lehmann, Jennifer A. Pietenpol · 2014 · Clinical Cancer Research
Structural Basis of Detection and Signaling of DNA Single-Strand Breaks by Human PARP-1
Sebastian Eustermann, Wing-Fung Wu, Marie-France Langelier, Ji‐Chun Yang, Laura E. Easton, Amanda A. Riccio, John M. Pascal, David Neuhaus · 2015 · Molecular Cell
Synthetic lethality: General principles, utility and detection using genetic screens in human cells
Sebastian M. B. Nijman · 2010 · FEBS Letters
A Decade of Systems Biology
Han‐Yu Chuang, Matan Hofree, Trey Ideker · 2010 · Annual Review of Cell and Developmental Biology
Homology-Directed Repair and the Role of BRCA1, BRCA2, and Related Proteins in Genome Integrity and Cancer
Chun-Chin Chen, Weiran Feng, Pei Xin Lim, Elizabeth M. Kass, Maria Jasin · 2017 · Annual Review of Cancer Biology
Practical classification of triple-negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies
Antonio Marra, Dario Trapani, Giulia Viale, Carmen Criscitiello, Giuseppe Curigliano · 2020 · npj Breast Cancer
Pathogenesis and heterogeneity of ovarian cancer
Paul Kroeger, Ronny Drapkin · 2016 · Current Opinion in Obstetrics & Gynecology
Tumour treating fields therapy for glioblastoma: current advances and future directions
Ola Rominiyi, Aurelie Vanderlinden, Susan Jane Clenton, Caroline H. Bridgewater, Yahia Al-Tamimi, Spencer James Collis · 2020 · British Journal of Cancer
Orthologous CRISPR–Cas9 enzymes for combinatorial genetic screens
Najm, Fadi J, Strand, Christine, Donovan, Katherine F, Hegde, Mudra, Sanson, Kendall R, Vaimberg, Emma W, Sullender, Meagan E, Hartenian, Ella, Kalani, Zohra, Fusi, Nicolo et al. · 2018 · Nature Biotechnology
Cancer Stem Cells Contribute to Cisplatin Resistance in Brca1/p53 –Mediated Mouse Mammary Tumors
Norazizah Shafee, Christopher R. Smith, Shuanzeng Wei, Yoon Hee Kim, Gordon Brent Mills, Gabriel N. Hortobágyi, Eric J. Stanbridge, Eva Y-H. P. Lee · 2008 · Cancer Research
Pathway choice in DNA double strand break repair: observations of a balancing act
Inger Brandsma, Dik C. van Gent · 2012 · Genome Integrity
Cooperation of breast cancer proteins PALB2 and piccolo BRCA2 in stimulating homologous recombination
Rémi Buisson, Anne‐Marie Dion‐Côté, Yan Coulombe, Hélène Launay, Hong Cai, Alicja Z. Stasiak, Andrzej Stasiak, Bing Xia, Jean‐Yves Masson · 2010 · Nature Structural & Molecular Biology
Collateral sensitivity as a strategy against cancer multidrug resistance
Kristen M. Pluchino, Matthew D. Hall, Andrew S. Goldsborough, Richard Callaghan, Michael M. Gottesman · 2012 · Drug Resistance Updates
Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs
Andrea Marion Marquard, Aron Charles Eklund, Tejal Joshi, Marcin Krzystanek, Francesco Favero, Zhigang C. Wang, Andrea L. Richardson, Daniel P. Silver, Zoltán Szállási, Nicolai J. Birkbak · 2015 · Biomarker Research
Biology and Management of Patients With Triple-Negative Breast Cancer
Sharma, Priyanka · 2016 · The Oncologist
BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency
Chaoyang Sun, Jun Yin, Yong Fang, Jian Chen, Kang Jin Jeong, Xiaohua Chen, Christopher P. Vellano, Zhenlin Ju, Wei Zhao, Dong Zhang et al. · 2018 · Cancer Cell
Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer
Sven Rottenberg, Anders O.H. Nygren, Marina Pajic, Fijs W. B. van Leeuwen, Ingrid van der Heijden, Koen van de Wetering, Xiaoling Liu, Karin E. de Visser, Kenneth G. A. Gilhuijs, Olaf van Tellingen et al. · 2007 · Proceedings of the National Academy of Sciences
Essential Gene Profiles in Breast, Pancreatic, and Ovarian Cancer Cells
Richard Marcotte, Kevin R. Brown, Fernando Suárez, Azin Sayad, Konstantina Karamboulas, Paul M. Krzyzanowski, Fabrice Sircoulomb, Mauricio Medrano, Yaroslav Fedyshyn, Judice L.Y. Koh et al. · 2011 · Cancer Discovery
Exploiting replicative stress to treat cancer
Matthias Dobbelstein, Claus Storgaard Sørensen · 2015 · Nature Reviews Drug Discovery
Topoisomerase levels determine chemotherapy response in vitro and in vivo
Darren J. Burgess, Jason D. Doles, Lars Zender, Wen Xue, Beicong Ma, William Richard McCombie, Gregory J. Hannon, Scott W. Lowe, Michael T. Hemann · 2008 · Proceedings of the National Academy of Sciences
Genetic Predisposition to Breast Cancer: Past, Present, and Future
Clare Turnbull, Nazneen Rahman · 2008 · Annual Review of Genomics and Human Genetics
The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo
Victoria Weston, Ceri Oldreive, Anna Skowrońska, David Graham Oscier, Guy Pratt, Martin J.S. Dyer, Graeme C.M. Smith, Judy E. Powell, Zbigniew Rudzki, Pamela R. Kearns et al. · 2010 · Blood
Translating insights from the cancer genome into clinical practice
Lynda Chin, Joe W. Gray · 2008 · Nature
Inhibiting WEE1 Selectively Kills Histone H3K36me3-Deficient Cancers by dNTP Starvation
Sophia X. Pfister, Enni Markkanen, Yanyan Jiang, Sovan Sarkar, Mick Woodcock, Giulia Orlando, Ioanna Mavrommati, Chen‐Chun Pai, Lykourgos‐Panagiotis Zalmas, Neele Drobnitzky et al. · 2015 · Cancer Cell
Triple‐negative breast cancer: Present challenges and new perspectives
Podo, Franca, Buydens, Lutgarde M.C., Degani, Hadassa, Hilhorst, Riet, Klipp, Edda, Gribbestad, Ingrid S., Van Huffel, Sabine, W.M. van Laarhoven, Hanneke, Luts, Jan, Monleon, Daniel et al. · 2010 · Molecular Oncology
BRCA1 and BRCA2: breast/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair
P.J. O'Donovan, David M. Livingston · 2010 · Carcinogenesis
Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition
Junko Murai, Ying Feng, Guoying Karen Yu, Yuanbin Ru, Sai-Wen Tang, Yuqiao Shen, Yves G. Pommier · 2016 · Oncotarget
Effects of hyperthermia on DNA repair pathways: one treatment to inhibit them all
Arlene L. Oei, Lianne E. M. Vriend, Johannes Crezee, Nicolaas A.P. Franken, Przemek M. Krawczyk · 2015 · Radiation Oncology
Rationale for Poly(ADP-ribose) Polymerase (PARP) Inhibitors in Combination Therapy with Camptothecins or Temozolomide Based on PARP Trapping versus Catalytic Inhibition
Junko Murai, Yiping Zhang, Joel Morris, Jiuping Jay Ji, Shunichi Takeda, James H. Doroshow, Yves G. Pommier · 2014 · Journal of Pharmacology and Experimental Therapeutics
BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers
Maxwell, Kara N., Wubbenhorst, Bradley, Wenz, Brandon M., De Sloover, Daniel, Pluta, John, Emery, Lyndsey, Barrett, Amanda, Kraya, Adam A., Anastopoulos, Ioannis N., Yu, Shun et al. · 2017 · Nature Communications
Systematic Mapping of Genetic Interaction Networks
Scott J. Dixon, Michael Costanzo, Anastasia Baryshnikova, Brenda Andrews, Charles M. Boone · 2008 · Annual Review of Genetics
Wnt signaling in triple-negative breast cancer
Sebastian Pohl, Naomi Brook, Mark Agostino, Frank Arfuso, Alan Prem Kumar, Arun Dharmarajan · 2017 · Oncogenesis
Nuclear Acetyl-CoA Production by ACLY Promotes Homologous Recombination
Sivanand, Sharanya, Rhoades, Seth, Jiang, Qinqin, Lee, Joyce V., Benci, Joseph, Zhang, Jingwen, Yuan, Salina, Viney, Isabella, Zhao, Steven, Carrer, Alessandro et al. · 2017 · Molecular Cell
Targeting DNA damage response in cancer therapy
Noriko Hosoya, Kiyoshi Miyagawa · 2014 · Cancer Science
Poly(ADP‐ribose)
Alexander Bürkle · 2005 · FEBS Journal
Targeted Therapies for Triple-Negative Breast Cancer: Combating a Stubborn Disease
Murugan Kalimutho, Kate Parsons, Deepak Mittal, José Alejandro López, Sriganesh Srihari, Kum Kum Khanna · 2015 · Trends in Pharmacological Sciences
DNA Double-Strand Break Repair as Determinant of Cellular Radiosensitivity to Killing and Target in Radiation Therapy
Emil Mladenov, Simon Magin, Aashish Soni, George E. Iliakis · 2013 · Frontiers in Oncology
Homologous recombination in cancer development, treatment and development of drug resistance
Thomas Helleday · 2010 · Carcinogenesis
BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer
Michele Moschetta, Angela Joy George, Stan B. Kaye, Susana N. Banerjee · 2016 · Annals of Oncology
Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition
Neil Johnson, Yuchen Li, Zandra E. Walton, Katherine A. Cheng, Danan Li, Scott J. Rodig, Lisa A. Moreau, Christine Unitt, Roderick Terry Bronson, Huw D. Thomas et al. · 2011 · Nature Medicine
Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer.
Y. Bang, S. Im, Keunsung Lee, J. Cho, E. Song, K. Lee, Yeul-Hong Kim, Joonoh Park, H. Chun, D. Zang et al. · 2015 · Journal of Clinical Oncology
Cancer Suppression by the Chromosome Custodians, BRCA1 and BRCA2
Ashok R. Venkitaraman · 2014 · Science
Targeted therapy for cancer using PARP inhibitors
Christopher J. Lord, Alan Ashworth · 2008 · Current Opinion in Pharmacology
PARP-1 Inhibition as a Targeted Strategy to Treat Ewing's Sarcoma
John Chad Brenner, Felix Yi-Chung Feng, Sumin Han, Sonam Patel, Siddharth V. Goyal, Laura M. Bou‐Maroun, Meilan Liu, Robert J. Lonigro, John R. Prensner, Scott A. Tomlins et al. · 2012 · Cancer Research
Marked for death: Targeting epigenetic changes in cancer
Pfister, Sophia Xiao, Ashworth, Alan · 2017 · Nature Reviews Drug Discovery
Tankyrase-targeted therapeutics: expanding opportunities in the PARP family
Jenna L. Riffell, Christopher J. Lord, Alan Ashworth · 2012 · Nature Reviews Drug Discovery
Mutational signatures: emerging concepts, caveats and clinical applications
Ching Chiek Koh, Andrea Degasperi, Xueqing Zou, Sophie Momen, Serena Nik‐Zainal · 2021 · Nature reviews. Cancer
Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities
Joshua Z. Press, Alessandro De Luca, Niki Boyd, Sean S Young, Armelle A. Troussard, Yolanda Ridge, Pardeep Kaurah, Steve E. Kalloger, Katherine A Blood, Margaret J. Smith et al. · 2008 · BMC Cancer
CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer
Tomoe Higuchi, Dallas B. Flies, Nicole A. Marjon, Gina M. Mantia-Smaldone, Lukas Ronner, Phyllis A. Gimotty, Sarah Foster Adams · 2015 · Cancer Immunology Research
Current Development of Clinical Inhibitors of Poly(ADP-Ribose) Polymerase in Oncology
Kapila Ratnam, Jennifer A. Low · 2007 · Clinical Cancer Research
DNA Repair Pathways in Clinical Practice: Lessons From Pediatric Cancer Susceptibility Syndromes
Richard D. Kennedy, Alan D. D’Andrea · 2006 · Journal of Clinical Oncology
Triple-negative breast cancer: Molecular features, pathogenesis, treatment and current lines of research
Ana Bosch, Pîlar Eroles, Rosa Zaragozá, Juan R. Vinã, Ana M. Lluch · 2010 · Cancer Treatment Reviews
Biallelic Mutations in BRCA1 Cause a New Fanconi Anemia Subtype
Sarah L. Sawyer, Lei Tian, Marketta Kähkönen, Jeremy Schwartzentruber, Martin Kircher, Jacek Majewski, David Alexandre Dyment, Allan Micheil Innes, Kym M. Boycott, Lisa A. Moreau et al. · 2014 · Cancer Discovery
Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer
Mohammad Asim, Firas Tarish, Heather Ireland Zecchini, Kumar Sanjiv, Eleni Gelali, Charles E. Massie, Ajoeb Baridi, Anne Yvonne Warren, Wanfeng Zhao, Christoph Ogris et al. · 2017 · Nature Communications
Mechanisms of DNA–protein crosslink repair
Julian Stingele, Roberto Bellelli, Simon J. Boulton · 2017 · Nature Reviews Molecular Cell Biology
Somatic Genomic Testing in Patients With Metastatic or Advanced Cancer: ASCO Provisional Clinical Opinion
Debyani Chakravarty, Amber Johnson, Jeffrey Sklar, Neal Ian Lindeman, Kathleen N. Moore, Shridar Ganesan, Christine Marie Lovly, Jane Perlmutter, Stacy W. Gray, Jimmy Hwang et al. · 2022 · Journal of Clinical Oncology
Envisioning the future of early anticancer drug development
Timothy Anthony Yap, Shahneen Kaur Sandhu, Paul Workman, Johann Sebastian De Bono · 2010 · Nature reviews. Cancer
Triple-negative/basal-like breast cancer: review
Emad A. Rakha, Ian Ogilvie Ellis · 2008 · Pathology
Cancer-specific defects in DNA repair pathways as targets for personalized therapeutic approaches
Felix Dietlein, Lisa Thelen, Hans Christian Reinhardt · 2014 · Trends in Genetics
Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2
Amit M. Oza, Anna V. Tinker, Ana Oaknin, Ronnie Shapira‐Frommer, Iain A. McNeish, Elizabeth M. Swisher, Isabelle Laure Ray-Coquard, Katherine M. Bell‐McGuinn, Robert Louis Coleman, David M. O’Malley et al. · 2017 · Gynecologic Oncology
Deregulated MYC expression induces dependence upon AMPK-related kinase 5
Lidan Liu, Jannes Ulbrich, Judith Müller, Torsten Wüstefeld, Lukas Aeberhard, Theresia R. Kress, Nathiya Muthalagu, Lukas Rycak, Ramona Rudalska, Roland Moll et al. · 2012 · Nature
Mechanism of Suppression of Chromosomal Instability by DNA Polymerase POLQ
Matthew J. Yousefzadeh, David W. Wyatt, Kei‐ichi Takata, Yunxiang Mu, Sean C. Hensley, Junya Tomida, Göran O. Bylund, Sylvie Doublié, Erik Johansson, Dale A. Ramsden et al. · 2014 · PLoS Genetics
The molecular pathology of cancer
Timothy Harris, Frank P. McCormick · 2010 · Nature Reviews Clinical Oncology
Emerging and evolving concepts in gene essentiality
Giulia Irene Rancati, Jason Moffat, Athanasios Typas, Norman Pavelka · 2017 · Nature Reviews Genetics
Parp‐1 protects homologous recombination from interference by Ku and Ligase IV in vertebrate cells
Helfrid Hochegger, Donniphat Dejsuphong, Toru Fukushima, Ciaran G. Morrison, Eiichiro Sonoda, Valérie Schreiber, Guang Zhao, Alihossein Saberi, Mitsuko Masutani, Noritaka Adachi et al. · 2006 · The EMBO Journal
PARP-1 and its associated nucleases in DNA damage response
Yijie Wang, Weibo Luo, Yingfei Wang · 2019 · DNA repair
Analysis of Circulating Cell-Free DNA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors
David Alan Quigley, Joshi J. Alumkal, Alexander William Wyatt, Vishal Kothari, Adam Foye, Paul Lloyd, Rahul Raj Aggarwal, Won Bae Kim, Eric Lu, Jacob A. Schwartzman et al. · 2017 · Cancer Discovery
BRCA Genes: The Role in Genome Stability, Cancer Stemness and Therapy Resistance
Ielizaveta Gorodetska, Iryna A. Kozeretska, Anna Dubrovska · 2019 · Journal of Cancer
Upregulation of Poly (ADP-Ribose) Polymerase-1 (PARP1) in Triple-Negative Breast Cancer and Other Primary Human Tumor Types
Valeria Ossovskaya, Ingrid Chou Koo, Eric Peter Kaldjian, C. Alvares, Barry M. Sherman · 2010 · Genes & Cancer
The BRCA1-Δ11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin
Yifan Wang, Andrea J. Bernhardy, Cristina Cruz, John J. Krais, Joseph Nacson, Émmanuelle Nicolas, Suraj Peri, Hanneke M.L. van der Gulden, Ingrid van der Heijden, Shane W. O’Brien et al. · 2016 · Cancer Research
Engineered cellular immunotherapies in cancer and beyond
A. Finck, Tatiana Blanchard, Christopher Roselle, G. Golinelli, C. June · 2022 · Nature Medicine
PARP inhibitors in the management of breast cancer: current data and future prospects
Luca Livraghi, Judy Ellen Garber · 2015 · BMC Medicine
The zinc-finger domains of PARP1 cooperate to recognize DNA strand breaks
Ammar A. E. Ali, Gyula Timinszky, Raquel Arribas-Bosacoma, Marek Kozłowski, Paul O. Hassa, Markus Hassler, Andreas G. Ladurner, Laurence H. Pearl, Antony W. Oliver · 2012 · Nature Structural & Molecular Biology
A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation
Marta Castroviejo‐Bermejo, Cristina Cruz, Alba Llop‐Guevara, Sara Gutiérrez‐Enríquez, Mandy Ducy, Yasir H. Ibrahim, Albert Gris‐Oliver, Benedetta Pellegrino, Alejandra Bruna, Marta Guzmán et al. · 2018 · EMBO Molecular Medicine
STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer
Qiwei Wang, Johann S. Bergholz, Liya Ding, Ziying Lin, Sheheryar Kairas Kabraji, Melissa E. Hughes, Xiadi He, Shaozhen Xie, Tao Jiang, Weihua Wang et al. · 2022 · Nature Communications
Triple negative breast cancers: Clinical and prognostic implications
Sarah‐Jane Dawson, Elena Provenzano, Carlos Caldas · 2009 · European Journal of Cancer
Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance
Neil Johnson, Shawn F. Johnson, Wei Yao, Yu-Chen Li, Young-Eun Choi, Andrea J. Bernhardy, Yifan Wang, Marzia Capelletti, Kristopher A. Sarosiek, Lisa A. Moreau et al. · 2013 · Proceedings of the National Academy of Sciences
The current state of molecular testing in the treatment of patients with solid tumors, 2019
El‐Deiry, Wafik S., Goldberg, Richard M., Lenz, Heinz‐Josef, Shields, Anthony F., Gibney, Geoffrey T., Tan, Antoinette R., Brown, Jubilee, Eisenberg, Burton, Heath, Elisabeth I., Phuphanich, Surasak et al. · 2019 · CA: A Cancer Journal for Clinicians
A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation — An NRG Oncology/Gynecologic Oncology Group study
Robert L. Coleman, Michael W. Sill, Katherine M. Bell‐McGuinn, Carol A Aghajanian, Heidi J. Gray, Krishnansu S. Tewari, Steven C. Rubin, Thomas Rutherford, John K. Chan, Alice P. Chen et al. · 2015 · Gynecologic Oncology
Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer
Britta Weigelt, Iñaki Comino‐Méndez, Ino de Bruijn, Lei Tian, Jane Lowe Meisel, Isaac García-Murillas, Charlotte Victoria Fribbens, Ros Cutts, Luciano Gastón Martelotto, Charlotte K.Y. Ng et al. · 2017 · Clinical Cancer Research
Activation of PARP-1 by snoRNAs Controls Ribosome Biogenesis and Cell Growth via the RNA Helicase DDX21
Dae-Seok Kim, Cristel V. Camacho, Anusha Nagari, Venkat S. Malladi, Sridevi Challa, W. Lee Kraus · 2019 · Molecular Cell
Targeting signaling pathways in prostate cancer: mechanisms and clinical trials
Yundong He, Weidong Xu, Yu‐Tian Xiao, Haojie Huang, Di Gu, Shancheng Ren · 2022 · Signal Transduction and Targeted Therapy